Everyone’s cheering the Matrix M integration like it’s a done deal, but I’m uneasy. PFE’s history with pneumococcal vaccines has been rocky, and NVAX’s 31 isn’t proven yet. Feels like marketing hype before real data.
Is NVAX backing out of the pneumonia race?
If NVAX hits 35% coverage with 10 serotypes and 30% efficacy, that’s a big win versus PFE’s 23-valent at ~50% coverage. But real-world data matters; 2023 trials showed 31’s efficacy was lower than projected.
If this scales adoption of open-source tools, it reinforces IBM’s cloud and services moat while Red Hat benefits from recurring support economics.
From a macro lens, this fits the trend of enterprises centralizing open-source governance while keeping costs under control. If rates stay higher-for-longer, bundled support and predictable spend matter more than ever.
Interesting move to bundle Red Hat’s support with Azure Marketplace; could lower enterprise friction for hybrid open-source workloads.
Seen this before: gold flows spike on headlines, then fade. Miners lag and reverse. Patience beats chasing these targets.
Holding GLD and GDXU—trim here or wait?
Targets look nice, but the gold miners are still whipsawed. If GLD slips under $315, spreads tighten and liquidity dries up. GDXU’s $38 target feels optimistic without a clear catalyst. I’m fading pops until risk-off confirms.
NVDA down 12%, SOXS up 18%—volumes suggest rotation.
If NVDA keeps sliding while SOXS pops, is this the dip-buy for NVDA and a starter in SOXS, or just noise before earnings? Anyone hedging with puts or waiting for a pullback?
AI chips hype feels stretched; data centers still volatile.
Not in yet, honestly. The headline screams buy, but I’m uneasy about the overvaluation angle. Might wait for a pullback into the 50-day before nibbling.
Is this a trend reversal or just noise?
